Last reviewed · How we verify
Cannabidiol Oral Solution [Epidiolex]
Cannabidiol modulates endocannabinoid signaling and multiple ion channels to reduce neuronal hyperexcitability and seizure activity.
Cannabidiol modulates endocannabinoid signaling and multiple ion channels to reduce neuronal hyperexcitability and seizure activity. Used for Dravet syndrome (severe myoclonic epilepsy of infancy), Lennox-Gastaut syndrome, Tuberous sclerosis complex-associated seizures.
At a glance
| Generic name | Cannabidiol Oral Solution [Epidiolex] |
|---|---|
| Also known as | Epidiolex |
| Sponsor | Silkiss Eye Surgery |
| Drug class | Cannabinoid anticonvulsant |
| Target | TRP channels, adenosine signaling, serotonin receptors (multi-target) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Cannabidiol (CBD) is a non-intoxicating cannabinoid that acts through multiple mechanisms including modulation of transient receptor potential (TRP) channels, enhancement of adenosine signaling, and effects on serotonin receptors. It reduces seizure frequency and severity in epilepsy by decreasing neuronal excitability without direct GABA receptor agonism. The exact molecular mechanisms remain incompletely understood but involve both cannabinoid receptor-independent and receptor-dependent pathways.
Approved indications
- Dravet syndrome (severe myoclonic epilepsy of infancy)
- Lennox-Gastaut syndrome
- Tuberous sclerosis complex-associated seizures
Common side effects
- Somnolence
- Diarrhea
- Fatigue
- Decreased appetite
- Elevated liver transaminases
- Rash
- Insomnia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol Oral Solution [Epidiolex] CI brief — competitive landscape report
- Cannabidiol Oral Solution [Epidiolex] updates RSS · CI watch RSS
- Silkiss Eye Surgery portfolio CI